What amount sold does SAB Biotherapeutics, Inc. report in Form D filings?

The latest linked filings report $182.5M sold across 2 identified offering(s). 0 unlinked amendment(s) are excluded; 0 offering(s) have no reported amount sold. This is not verified lifetime funding or money raised during a specific period.

When was SAB Biotherapeutics, Inc.'s most recent SEC filing?

SAB Biotherapeutics, Inc.'s most recent Form D filing was on 2025-08-05.

How many investors does SAB Biotherapeutics, Inc. have?

The most recent Form D filing lists 17 investor(s).

What type of securities does SAB Biotherapeutics, Inc. offer?

SAB Biotherapeutics, Inc.'s SEC Form D filings indicate equity offerings.

SAB Biotherapeutics, Inc.

CIK: 0001833214·Biotechnology·Miami Beach, FL·Corporation·Founded 2020

Reported Sold

$182,500,000

Total Filings

Identified Offerings

Last Filed

Aug 5, 2025

Employees

—

Reported sold uses the latest linked filing for each identified offering; it is not verified lifetime funding. SPV filings are shown separately.

About

Company in Biotechnology industry

SEC EDGAR

Offering filing timeline

Aug 5, 2025Form D — New notice

Reported sold: $175,000,000 · Target: $175,000,000

Rule 506(b)·17 investors

Oct 16, 2023Form D — New notice

Reported sold: $7,500,000 · Target: $7,500,000

Rule 506(b)·13 investors

Fundraising Profile

Exemptions

Rule 506(b)

Investors in latest filing

Revenue Range

Decline to Disclose

Reported commissions across identified offerings

$10,950,000

Amendment Rate

Latest reported sold across 2 identified offerings

$182,500,000

Uses the latest linked filing for each offering. This is not a measure of money raised in the last year or verified lifetime funding.

Key People

Eddie Sullivan

Related Person

Appears on 1 filing

Katie Ellias

Related Person

Appears on 1 filing

Scott Giberson

Related Person

Appears on 1 filing

Christine Hamilton

Related Person

Appears on 1 filing

David Link

Related Person

Appears on 1 filing

Erick Lucera

Related Person

Appears on 1 filing

Andrew Moin

Related Person

Appears on 1 filing

Samuel Reich

Related Person

Appears on 1 filing

Filing History

Date	Type	Offering target	Reported sold	Investors
Aug 5, 2025	New	$175,000,000	$175,000,000	17
Oct 16, 2023	New	$7,500,000	$7,500,000	13

Filing History

Amendment insights

Loading amendment history…

Comparable issuers

Matched on reported industry and issuer type, then ranked by business location, offering target, and recency. These are filing comparables, not verified business competitors.

Syncromune, Inc.

Biotechnology

Offering target: $144,828,791

Filed May 11, 2026